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Inhibitors of DNA binding (IDs) antagonize basic-
helix-loop-helix (bHLH) transcription factors to inhibit
differentiation and maintain stem cell fate. ID ubiqui-
tination and proteasomal degradation occur in differ-
entiated tissues, but IDs in many neoplasms appear
to escape degradation. We show that the deubiquiti-
nating enzyme USP1 promotes ID protein stability
and stem cell-like characteristics in osteosarcoma.
USP1 bound, deubiquitinated, and thereby stabilized
ID1, ID2, and ID3. A subset of primary human osteo-
sarcomas coordinately overexpressed USP1 and ID
proteins. USP1 knockdown in osteosarcoma cells
precipitated ID protein destabilization, cell-cycle
arrest, and osteogenic differentiation. Conversely,
ectopic USP1 expression in mesenchymal stem cells
stabilized ID proteins, inhibited osteoblastic differen-
tiation, and enhanced proliferation. Consistent with
USP1 functioning in normal mesenchymal stem cells,
USP1-deficient mice were osteopenic. Our observa-
tions implicate USP1 in preservation of the stem
cell state that characterizes osteosarcoma and iden-
tify USP1 as a target for differentiation therapy.
INTRODUCTION
Basic-helix-loop-helix (bHLH) transcription factors comprise the
third-largest family of recognized transcription factors in the
human genome (Tupler et al., 2001) and are essential regulators
of development and differentiation through binding DNA ele-
ments termed E boxes (Massari and Murre, 2000). Class I
bHLH homodimers are expressed broadly and promote expres-
sion of antiproliferative genes such as CDKN1A, CDKN2A, and
CDKN2B (Yokota and Mori, 2002). Class II bHLH proteins
show more restricted expression and form heterodimers with918 Cell 146, 918–930, September 16, 2011 ª2011 Elsevier Inc.class I proteins to drive tissue-specific genes such as IGH@
and SP7/OSTERIX (Lassar et al., 1991; Weintraub et al., 1994).
Through the combined induction of tissue-specific and antipro-
liferative genes, bHLH transcription factors serve as integrators
of lineage commitment.
DNA binding of bHLH proteins is limited by heterodimerization
with inhibitor of DNA-binding proteins, or IDs. The ID family
consists of four members, ID1, ID2, ID3, and ID4 (Lasorella
et al., 2001), with overlapping spatial and temporal expression
profiles. All four IDs bind the various bHLH proteins with similar
affinities to regulate gene expression (Prabhu et al., 1997). IDs
are essential for mammalian development; disruption of two or
more ID genes results in embryonic lethality (Lyden et al.,
1999). In contrast, overexpression of ID proteins in transgenic
mice produces fatal malignancies (Kim et al., 1999). Similarly,
elevated ID protein levels are observed in a broad range of
dedifferentiated primary human malignancies ranging from
pancreatic carcinoma to neuroblastoma (Perk et al., 2005).
Although ID proteins are scarce in normal adult differentiated
tissues, they are abundant in proliferating tissues, including
embryonic and adult stem cell populations, which suggests
that IDs might maintain ‘‘stemness’’ (Yokota and Mori, 2002).
The stem cell expression and tumor-promoting qualities of ID
proteins suggest that ID genes may be pivotal in cancer stem
cell biology. An engineered ID-suppressing HLH protein was
reported to differentiate neuroblastoma tumors (Ciarapica
et al., 2009).
IDs are induced transcriptionally by myriad growth factors
including bone morphogenic proteins, platelet-derived growth
factor, epidermal growth factor, as well as by T cell receptor liga-
tion (Yokota and Mori, 2002). ID1, ID2, and ID3, but not ID4, are
subject to K48-linked polyubiquitination and subsequent degra-
dation by the 26S proteasome. Consequently, IDs are short lived
in most tissues (Bounpheng et al., 1999). The ubiquitously ex-
pressed APC/Cdh1 complex is an E3 ubiquitin ligase that
governs ID stability and abundance (Lasorella et al., 2006), but
ID proteins are stable in some contexts. Therefore, we sought
a deubiquitinating enzyme that counters ID ubiquitination.
We show that USP1 deubiquitinates and stabilizes ID1, ID2,
and ID3, resulting in their increased abundance. Significantly,
elevated USP1 protein and mRNA in a subset of primary osteo-
sarcoma tumors correlated with increased ID protein levels.
USP1 knockdown in osteosarcoma cells caused ID protein
destabilization, p53-independent induction of CDKN1A encod-
ing cyclin-dependent kinase inhibitor (CDKI) p21, and cell-
cycle arrest. In addition, expression of mesenchymal stem cell
markers was decreased and osteogenic differentiation resumed.
These data suggest that osteosarcomas, like acute promyelo-
cytic leukemia, may be amenable to differentiation therapies
(Soignet et al., 1998). In contrast to USP1 knockdown, USP1
overexpression in primary human mesenchymal stem cells
(hMSCs) caused ID protein accumulation and interfered with
normal differentiation. Indeed, USP1 promoted transformation
in a mesenchymal cell line. Finally, loss of Usp1 in gene-targeted
mice caused severe osteopenia, which is consistent with a role
for USP1 in the mesenchymal lineage. Our results strongly sug-
gest that USP1 has oncogenic potential and promotes tumori-
genesis through disruption of normal mesenchymal stem cell
commitment and differentiation.
RESULTS
USP1 Deubiquitinates and Stabilizes ID Proteins
To identify deubiquitinases (DUBs) that stabilize ID proteins, we
overexpressed 94 human DUBs with C-terminal Flag epitopes
in 293T cells and assessed endogenous ID2 abundance by
western blot (see Table S1 available online). 293T cells degrade
ID2 in a proteasome-dependent manner because ID2 accumu-
lates after treatment with the proteasome inhibitor MG-132
(Figure S1A). DUBs that increased endogenous ID2 were
USP36, JOSD2, USP33, SENP3, SENP5, USP37, OTUD5,
USP9Y, USP45, and USP1 (Figure S1A). To exclude indirect
mechanisms increasing ID2 expression, we focused on ID2-in-
teracting DUBs USP1 and USP33 (Figure S1B). However, unlike
USP1, USP33 lacked deubiquitinating activity against ID2 (data
not shown).
To determine whether USP1 extended the half-life of ID2, we
transfected 293T cells with USP1 and monitored ID2 abundance
after treatment with the translational inhibitor cycloheximide. In
the absence of new protein synthesis, ID2 was cleared rapidly
from cells transfected with a control vector, with a half-life of
approximately 2min (Figure 1A). Overexpressed USP1 extended
the half-life of ID2 to over 80 min. The proteolytic activity of
USP1 was necessary for ID2 accumulation because the catalyt-
ically inactive point mutant USP1 C90S (Nijman et al., 2005)
neither increased the half-life of ID2 (Figure 1A) nor altered ID2
steady-state abundance (Figure 1B). Similar results were ob-
tainedwith ID1 and ID3. USP1 appeared to target IDs specifically
because it did not enhance expression of labile IkBa (Palombella
et al., 1994).
Next, we assessed the effect of USP1 on ID2 ubiquitination.
Wild-type USP1, but not USP1 C90S, reduced the amount of
ID2 modified with HA-tagged ubiquitin (Figure 1C). Both basal
and USP1-induced ID2 deubiquitination was enhanced by coex-
pression of USP1 cofactorWDR48 (Cohn et al., 2007) (Figure 1C).
To address whether USP1 deubiquitinated ID2 directly, ubiquiti-nated ID2 purified from 293T cells was incubated in vitro with
either wild-type USP1 or USP1 C90S purified separately from
293T cells. Ubiquitinated ID2 was decreased by wild-type
USP1 but not USP1 C90S (Figure 1D), indicating that deubiquiti-
nation was unlikely a consequence of a coeluted protease. The
decrease in ID2 ubiquitination also was sensitive to N-ethylma-
leimide, confirming the involvement of a cysteine protease
(Figure 1D). Consistent with ubiquitinated ID2 being a USP1
substrate, deletion mutant USP1D260–300 interacted poorly
with ID2 (Figure S1C) and did not enhance ID2 abundance
(Figure S1D).
USP1 and ID2 Are Coordinately Overexpressed in
a Subset of Primary Osteosarcoma Tumors
To identify a biological context in which USP1 deubiquitinates ID
proteins, we examined USP1 expression patterns. Microarray
analyses of healthy and diseased human tissues revealed that
osteosarcoma tumors expressed more USP1 mRNA than
healthy or osteoarthritic bone biopsies (Figure 2A). Western blot-
ting of a separate set of primary human osteosarcoma biopsies
found that USP1 was elevated in 7 of 14 osteosarcomas when
compared to 3 normal primary human osteoblast samples (Fig-
ure 2B). Strikingly, ID2 protein abundance in these primary
human tumor samples correlated well with USP1 abundance.
One anomalous sample contained abundant USP1 but little
ID2 (Figure 2B, lane 6), perhaps due to poor expression of the
USP1 cofactor WDR48. Another sample contained abundant
ID2 and little USP1 (Figure 2B, lane 16), which may reflect
reduced ID2 ubiquitination or that other DUBs are active.
The amount of USP1 protein in the primary osteosarcomas
correlated largely with USP1 mRNA abundance (Figure 2C),
suggesting that elevated USP1 in osteosarcoma is due to tran-
scriptional upregulation. In contrast, ID2 protein and mRNA
levels correlated poorly (Figure 2D). The coincident overexpres-
sion of USP1 and ID2 in primary osteosarcomawas confirmed by
immunohistochemistry (Figures 2E–2G). These results strongly
suggest that USP1 modifies ID proteins posttranslationally in
osteosarcoma.
USP1 Stabilizes ID Proteins in Osteosarcoma
We also assessed USP1 abundance and ID2 stability in human
osteosarcoma cell lines and in primary osteoblasts (Figure S2A).
In U2-OS osteosarcoma cells, USP1 was elevated, and the nor-
mally labile ID2was stable (Figures S2A and S2B). Knockdown of
USP1 with two distinct USP1 shRNAs caused a reduction in ID1,
ID2, and ID3 but had no effect on ID4 (Figure 3A). ID1, ID2, and
ID3 mRNAs were not reduced, excluding decreased transcrip-
tion as the reason for the drop in ID protein abundance (Fig-
ure S3I). USP1 knockdown specificity was confirmed with
shRNA-resistant USP1, which restored ID1, ID2, and ID3 to basal
levels. USP1 catalytic activity was essential for ID stability
because shRNA-resistant USP1 C90S did not restore ID protein
levels. Similar results were observed in osteosarcoma cell lines
HOS, SAOS, and SJSA (Figure S2C). USP1 knockdown did not
impact ID2 abundance in MG-63 osteosarcoma cells, likely
because these cells express very little WDR48 (Figure S2C).
Consistent with WDR48 deficiency limiting USP1 activity in
MG-63 cells, ectopic WDR48 increased ID2 (Figure S2D).Cell 146, 918–930, September 16, 2011 ª2011 Elsevier Inc. 919
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Figure 1. USP1 Deubiquitinates and Stabilizes ID Proteins
(A) Western blot (WB) analysis of 293T cells transfected with vector only (CTL), wild-type USP1 (WT), or catalytically inactive USP1 C90S. Cells were treated with
25 mg/ml cycloheximide (CHX) for the times indicated (left panel). ID2 was quantified by densitometry (right panel).
(B) 293T cells were cotransfected with Flag-tagged ID1, ID2, ID3, or IkBa, and empty vector (CTL), wild-type USP1, or USP1 C90S. Where indicated, cells were
treated with 10 mM MG-132 for 4 hr.
(C) Deubiquitination of ID2-Flag by USP1 or USP1 C90S and WDR48 in 293T cells cotransfected with HA-tagged ubiquitin.
(D) USP1-Flag, USP1 C90S-Flag, WDR48-Flag, and ubiquitinated ID2-Flag were affinity purified separately from 293T extracts and then combined together for
6 hr in an in vitro deubiquitination assay. NEM, N-ethylmaleimide.
See also Figure S1.To determine if USP1 knockdown and decreased IDs 1–3
modulated bHLH transcriptional activity, U2-OS cells were
transfected with an E box-driven luciferase reporter gene.
USP1 shRNAs enhanced expression of this reporter 7- to
10-fold over a control shRNA, consistent with activation of
bHLH proteins when ID proteins are decreased (Figure 3B).
shRNA-resistant wild-type USP1, but not USP1 C90S, sup-
pressed E box-driven reporter activity caused by USP1 knock-
down, confirming that USP1 catalytic activity is required for
bHLH-dependent transcription as well as ID protein stabilization.
The acute loss of IDs 1–3 following knockdown of endogenous
USP1 suggested ID protein destabilization via proteasome-
mediated degradation. As anticipated, the proteasome inhibitor
MG-132 did not by itself alter ID protein abundance in U2-OS
cells, suggesting that the IDs are intrinsically stable in cells that920 Cell 146, 918–930, September 16, 2011 ª2011 Elsevier Inc.express USP1 highly (Figure 3C). However, MG-132 treatment
did restore ID expression after USP1 knockdown, indicating
that ID proteins are subject to proteasome-mediated clearance
upon USP1 depletion. In keeping with this scenario, USP1
knockdown in MG-132-treated U2-OS cells increased the
amount of ubiquitinated ID2 (Figure 3D).
Next, we confirmed that endogenous USP1 associates with an
endogenous ID in osteosarcoma cells. ID2 coimmunoprecipi-
tatedwith endogenous USP1 fromU2-OS cells (Figure 3E), albeit
not with 1:1 stoichiometry, but this is to be expected for a
transient enzyme-substrate interaction. Similar results were
obtained in HOS cells (Figure S2E). USP1 also coimmunopreci-
pitated with ID2 (Figure 3F). Collectively, our results suggest
that USP1 is a potent DUB and stabilizing factor for ID1, ID2,
and ID3 in osteosarcoma.
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Figure 2. USP1 Is Overexpressed in Osteosarcoma and Correlates with ID2 Protein Expression
(A) Box and whisker plots of USP1 mRNA expression in primary human bone biopsies from normal and diseased tissue.
(B) Western blot (WB) analysis of USP1 and ID2 protein expression in primary human osteoblasts and osteosarcoma tumor samples.
(C and D) RT-PCR quantification of USP1 (C) and ID2 (D) expression in the samples in (B). Bars represent the mean ± SD of triplicate observations.
(E and F) Immunohistochemical detection of ID2 in 293T cells transfected with an ID2 expression vector (top panel) or an ID2 shRNA (bottom panel) (E) or in
a primary human osteosarcoma biopsy (F).
(G) Immunohistochemical staining of USP1 and ID2 in serial sections from primary osteosarcoma tissue. Control staining was with an isotype-control antibody.ID2 stabilization by USP1 was not limited to the setting of
osteosarcoma. USP1/ DT40 chicken B cells (Oestergaard
et al., 2007) expressed less ID2 protein than their wild-type coun-
terparts (Figure S2F) despite expressing similar levels of ID2
mRNA (Figure S2G). Consistent with USP1 deubiquitinating
and stabilizing ID2, proteasome inhibition with MG-132 in-
creased ID2 in USP1/, but not wild-type, DT40 cells (Fig-
ure S2H). In addition, USP1/ DT40 cells reconstituted with
wild-type USP1, but not USP1 C90S, contained equivalent ID2
to wild-type DT40 cells (Figure S2I).USP1 Suppresses p21-Mediated Cell-Cycle Arrest
in Osteosarcoma
One potential consequence of USP1 deficiency and increased
bHLH transcriptional activity in osteosarcoma cells is induction
of bHLH-regulated CDKI p21. Indeed, p21 was increased in
U2-OS cells transfected with USP1 shRNAs relative to cells
transfected with a control shRNA (Figure 4A). shRNA-resistant
wild-type USP1, but not USP1 C90S, reduced p21 to levels
observed in control cells, confirming knockdown specificity in
this setting. The tumor suppressor p53, a well-known inducerCell 146, 918–930, September 16, 2011 ª2011 Elsevier Inc. 921
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Figure 3. USP1 Physically Engages and Stabilizes ID Proteins in Osteosarcoma
(A) Western blot (WB) analysis of U2-OS cells cotransfected with USP1 or control (CTL) shRNAs, plus either empty vector (CTL) or shRNA-resistant USP1
(wild-type [WT] or USP1 mutant C90S).
(B) Luciferase activity of U2-OS cells treated as in (A) and cotransfected with an E box-driven luciferase reporter. Bars represent the mean ± SD of triplicate
observations.
(C) U2-OS cells were transfected with shRNAs and, where indicated, treated with 10mM MG-132 for 4 hr.
(D) U2-OS cells were cotransfected with ID2-Flag, HA-ubiquitin, and either CTL orUSP1 shRNAs. Where indicated, cells were treated with 10mMMG-132 for 4 hr.
ID2-Flag was immunoprecipitated from SDS/heat-denatured cell lysates.
(E and F) USP1 (E) or ID2 (F) was immunoprecipitated from U2-OS cells. Control immunoprecipitations were with nonspecific IgG. Asterisk (*) denotes a band of
unknown identity recognized by the anti-ID2 antibody.
See also Figure S3.of CDKN1A, was not increased by USP1 knockdown, suggest-
ing that increased p21 was p53 independent.
p21 is a potent inhibitor of cell cycle progression (Polyak et al.,
1996), so we assessed the proliferative capacity of U2-OS cells
following USP1 knockdown. Consistent with increased p21,
USP1 knockdown reduced U2-OS cell proliferation (Figure 4B
and Figure S3A). shRNA-resistant wild-type USP1, but neither
USP1 C90S nor USP1D260–300, restored cell proliferation
(FiguresS3BandS3C), indicating thatbothUSP1catalytic activity
and ID substrate recognition are required to maintain U2-OS cell
proliferation. USP1 knockdown similarly reduced proliferation in
HOS, SAOS, and SJSA, but not MG-63 osteosarcoma cells (Fig-
ure S3D). Flow cytometric analysis of the DNA content in U2-OS
cells afterUSP1knockdown revealed amoderate increase in cells922 Cell 146, 918–930, September 16, 2011 ª2011 Elsevier Inc.inG1andG2phasesof the cell cyclewith apronounced reduction
ofcells inSphase (Figure4CandFigureS3E).Apoptosis induction
following USP1 knockdown was not prominent; few cells with
a subdiploid DNA content were observed, there was no increase
in cells stained with annexin V, and increased processing of
caspase-3 was not detected (Figure S3E; data not shown).
Significantly, CDKN1A siRNAs restored S phase entry in USP1-
deficient U2-OS cells (Figure S3F and S3G), indicating that p21
is essential for the cell-cycle arrest induced byUSP1 knockdown.
USP1 Regulates p21 Expression and Cell-Cycle Arrest
in Osteosarcoma via ID Proteins
If ID degradation in the absence of USP1 caused p21 induction,
then knockdown of the ID proteins should phenocopy USP1
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Figure 4. USP1 Regulates Cell Cycling via ID Proteins in Osteosarcoma
(A) Western blot (WB) analysis of U2-OS cells treated as in Figure 3A.
(B) Outgrowth of U2-OS cells treated as in (A) was enumerated after 5 days of culture.
(C) Cell cycle status of propidium iodide-stained U2-OS cells treated as in (A).
(D) U2-OS cells transfected with indicated shRNAs and control or CDKN1A/p21 siRNAs.
(E) Quantification of cells in S phase in cells treated as in (D).
(F) U2-OS cells transfected with indicated shRNAs and shRNA-resistant USP1 (shRes USP1), ID1, ID2, and ID3, or control expression vectors.
(G) Quantification of cells in S phase in U2-OS cells treated as in (F).
Bars represent the mean ± SD of triplicate observations.
See also Figure S4.
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knockdown. shRNA knockdown of IDs 1–3 individually did not
alter p21 levels, but combined knockdown of ID1, ID2, and ID3
increased p21 similar to USP1 knockdown (Figure S3H). ID-
and USP1-deficient cells also expressed comparable levels of
CDKN1A mRNA (Figure S3I). Consistent with these observa-
tions, ID deficiency caused cell-cycle arrest similar to USP1 defi-
ciency (Figures S3J and S3K), and this was rescued by p21
knockdown (Figures 4D and 4E).
CDKN1A is regulated by many transcription factors, including
p53, which is activated in response to DNA damage (Kastan
et al., 1991). p53 knockdown inhibited etoposide-induced p21
in U2-OS cells but did not block the increase in p21 protein
seen after USP1 knockdown (Figure S3L), supporting a p53-
independent mechanism of p21 induction. Because USP1 is re-
ported to target PCNA and FANCD2 during DNA repair (Nijman
et al., 2005; Huang et al., 2006), we also checked if USP1 knock-
down produced DNA damage. H2AX phosphorylation that is
associated with DNA damage (Rogakou et al., 1999) increased
after etoposide treatment but not USP1 knockdown (data not
shown). These observations, combined with the ability of USP1
shRNAs to arrest p53-deficient SAOS cells (Figure S3D), exclude
general DNA damage, and p53 in particular, as intermediaries in
p21 induction following USP1 knockdown.
We confirmed that USP1 regulates p21 expression and cell
cycling via the IDs by rescuing the effects of USP1 knockdown
in U2-OS cells with ectopic expression of ID1, ID2, and ID3. ID
expression in USP1-depleted cells inhibited p21 expression
(Figure 4F) and blocked cell-cycle arrest (Figure 4G). Taken
together, our results demonstrate that USP1 suppresses p21
via ID protein stabilization and inhibition of bHLH transcriptional
activity in osteosarcoma.
USP1 and ID Proteins Restrict Osteogenic Commitment
in Osteosarcoma
Osteosarcomas are heterogeneous tumors comprised of disorga-
nized masses of osteoblasts, chondrocytes, and adipocytes.
These tumors are thought to develop from a mesenchymal stem
cell population that can give rise to all three lineages (Tang et al.,
2008). Accordingly, osteosarcoma cell lines fail to express clas-
sical osteoblast markers such as RUNX2, OSTERIX, SPARC/
OSTEONECTIN, and alkaline phosphatase (ALP) (Luo et al.,
2008).Osteosarcomacell lines also express surfacemarkers char-
acteristic ofmesenchymal stemcells, includingCD90,CD105, and
CD106 (Di Fiore et al., 2009). In light of the role that IDs play in stem
cell maintenance and regulation of differentiation, we investigated
whether either USP1 or ID knockdown in osteosarcoma would
trigger osteoblastic differentiation. U2-OS cells transfected with
USP1 or ID shRNAs expressed less CD105, CD106, and CD90
relative to control cells, whereas all cells expressed equivalent
amounts of the unrelated surface marker CD144 (Figure S4A).
Similar results were observed with HOS, SJSA, and SAOS cell
lines. USP1 or ID knockdown also increased expression of osteo-
blastic RUNX2, OSTERIX, and OSTEONECTIN (Figure S4B), and
increased ALP activity (Figure S4C). Increased E-cadherin expres-
sion and reduced N-cadherin and fibronectin following USP1
knockdown in U2-OS cells indicated a reversal of the epithelial to
mesenchymal transition that accompanies the malignant state of
osteosarcoma(Figures5Aand5B) (Thieryetal., 2009).Collectively,924 Cell 146, 918–930, September 16, 2011 ª2011 Elsevier Inc.these data suggest that ID protein stabilization by USP1 in osteo-
sarcoma blocks a normal osteogenic differentiation program.
The potential of USP1 inhibition as a tumor differentiation
strategy was investigated in the 143B osteosarcoma xenograft
model. A doxycycline-induced USP1 shRNA suppressed USP1
expression and reduced ID1 and ID2 in the xenografts (Figure 5C
and Figure S4D). ID3 was not detectable in this setting (data
not shown). USP1 knockdown also reduced 143B tumor
growth (Figure 5D), promoted OSTEONECTIN, RUNX2, SPP1/
OSTEOPONTIN, OSTERIX, and BGLAP/OSTEOCALCIN ex-
pression (Figure 5E and Figure S4E), and enhanced ALP activity
(Figure 5F). Remarkably, four of ten USP1-deficient xenograft
tumors achieved stasis and differentiation in situ, displaying
markedly altered cellular morphology and accumulation of
acellular collagenous masses consistent with proto-ossification
(Figure 5G). The tumors that continued to proliferate showed
evidence of escape from knockdown, presumably due to loss
or silencing of the shRNA (Figure S4F). These data indicate
that reducing USP1 is sufficient to initiate an osteogenic differen-
tiation program in osteosarcoma.
Dysregulated USP1 Expression Inhibits hMSC
Differentiation
Next, we determined if USP1 stabilization of the IDs contributes
to normal mesenchymal stem cell maintenance. USP1 was ex-
pressed in primary hMSCs but declined steadily as the cells
were cultured in conditions favoring osteoblastic differentiation
(Figure 6A). Consistent with a previous study (Peng et al., 2003),
ID1 and ID2 were induced transiently and then declined as well.
ID3 was not detected (data not shown). These data, together
with a study showing that misregulated ID expression inhibits
osteogenic differentiation (Peng et al., 2004), prompted us
to investigate whether USP1 overexpression disrupts hMSC
differentiation. hMSCs overexpressing USP1 and cultured in
osteogenic differentiation medium expressed abnormally high
levels of ID1 and ID2 (Figure 6B), exhibited low ALP activity (Fig-
ure 6C), showed minimal induction of RUNX2, OSTERIX, and
OSTEONECTIN (Figure 6D), and stained poorly with alizarin
red, which reveals mineral deposition that is a classic marker of
osteoblast activity (Figure 6E). These data imply that the hMSCs
overexpressing USP1 failed to differentiate. A similar differentia-
tion defectwas observed in hMSCsoverexpressing ID2,whereas
hMSCs overexpressing USP1 C90S differentiated similarly to
control cells. Thus, the catalytic activity of USP1 was necessary
and ID stabilization sufficient to inhibit osteogenic differentiation.
Coincident with their apparent failure to differentiate, hMSCs
overexpressing USP1 or ID2 proliferated significantly in the pres-
ence of excess osteogenic differentiation factors (Figure 6F). In
contrast, proliferation of control hMSCs, or those expressing
USP1 C90S, slowed as they differentiated in culture. Collec-
tively, our observations suggest that overexpression of USP1
or ID2 is sufficient to block osteoblastic differentiation, promote
retention of stem-like features, and render cells resistant to
differentiation cues.
USP1 Promotes Transformation and Tumor Formation
The ability of USP1 to inhibit mesenchymal stem cell differ-
entiation and sustain proliferation of osteosarcoma cell lines
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Figure 5. USP1 Promotes Retention of Stem Cell Identity in Osteosarcoma
(A) Western blot (WB) analysis of U2-OS cells transfected with CTL or USP1 shRNAs.
(B) Cells in (A) were stained and analyzed by fluorescence microscopy.
(C) Immunohistochemical staining for USP1 or ID2 in xenografts of 143B cells with doxycycline (DOX)-inducible shUSP1.
(D) Quantification of tumor volume of 143B xenografts as described in (C). Bars represent the mean ± SD of ten xenografts.
(E and F) RT-PCR quantification ofUSP1, ID2,OSTEONECTIN (ON),RUNX2 (RX2),OSTERIX (OSX), andOSTEOPONTIN (OP) mRNA levels (E) and ALP activity (F)
from 143B xenografts in (C). Bars represent the mean ± SD of triplicate observations.
(G) Representative xenograft tumors from (C) were stained with hematoxylin and eosin (H&E) or trichrome stain.
Scale bars, 100 mm.
See also Figure S5.suggested that USP1 might promote cell transformation. We
explored this possibility with NIH 3T3 cells stably transduced
with empty vector, ID2, USP1, or USP1 C90S. Wild-type USP1
increased expression of IDs 1–3 (Figure S5A) and caused
anchorage-independent cell proliferation in soft agar (Fig-
ure S5B), which is a classic hallmark of oncogenic transformation
(Hanahan and Weinberg, 2000). In contrast, cells transduced
with empty vector or USP1 C90S did not grow well in soft agar
(Figures S5B and S5C). Interestingly, USP1 produced larger
and more numerous colonies than ID2 (Figure S5C), suggesting
that stabilization of multiple ID proteins may be more transform-
ing than ID2 overexpression alone.
Our in vitro observations were recapitulated in vivo when NIH
3T3 cells were implanted subcutaneously into C.B-17 SCID.bg
mice. Control cells and cells expressing USP1 C90S failed to
produce measurable tumors, whereas cells overexpressing
USP1 or ID2 produced measurable tumors as early as 7 days
postimplantation (Figure S5D). Gross visual inspection of tumorsat the study endpoint confirmed that cells overexpressing USP1
or ID2 produced aggressive malignancies (Figure S5E). Similar
results were observed in NCr nude mice.
We assessed the contribution of the IDs to NIH 3T3 cell
transformation by USP1with Id1, Id2, and Id3 shRNAs. Suppres-
sion of IDs 1–3 (Figure S5F) blocked colony formation in soft
agar (Figure S5G), indicating that the IDs are essential for
USP1 transformation of NIH 3T3 cells.
USP1 Regulates Bone Development
Because USP1 overexpression impaired osteoblastic differenti-
ation of mesenchymal precursors, whereas USP1 loss caused
osteoblastic differentiation of osteosarcoma cells, we investi-
gated whether USP1 regulates normal bone development with
Usp1 gene-targeted mice. P12 Usp1/ mice were osteopenic
with defects in ossification of the cranial and long bones (Fig-
ure 7A). Underdeveloped sternal ribs likely contribute to the
lethal cyanotic respiratory failure in Usp1/ pups (Kim et al.,Cell 146, 918–930, September 16, 2011 ª2011 Elsevier Inc. 925
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Figure 6. USP1 and IDs Regulate Mesenchymal Stem Cell Differentiation
(A) Western blot (WB) analysis of hMSCs grown in osteogenic differentiation medium (ODM), or in nondifferentiating medium (Un).
(B) hMSCs were transduced with ID2, USP1 wild-type (WT), USP1 C90S, or empty vector (CTL) and cultured in ODM for 9 days.
(C and D) hMSCs in (B) were assessed for ALP activity (C) and OSTEONECTIN, RUNX2, and OSTERIX mRNA (D). Bars represent the mean ± SD of triplicate
observations.
(E) hMSCs in (B) stained with alizarin red to visualize calcium deposition. Scale bars, 100 mm.
(F) Enumeration of hMSCs in (B) after the indicated number of days of culture. Bars represent the mean ± SD of triplicate observations.
See also Figure S6.2009). Bone mineral density and volume in Usp1/ neonates
and E18.5 embryos were much less than in wild-type littermates
(Figures 7B and 7C and Figures S6B and S6C). Neither FANCD2-
nor PCNA-deficient mice exhibit perinatal lethality (Parmar et al.,
2010; Roa et al., 2008), excluding destabilization of these USP1
substrates as the primary cause of the perinatal lethality associ-
ated with USP1 deficiency.
Usp1/ and Usp1+/+ femurs contained similar numbers of
resting, transitional, proliferating, and hypertrophic chondro-
cytes, but deposition of osteoid on emergent bone spicules
was diminished, suggesting reduced activity of osteoid-depos-
iting osteoblasts (Figures S6D–S6F). Consistent with a defect
in osteoblast function, serum levels of bone alkaline phospha-
tase (BALP), a marker of systemic osteoblast activity, were
reduced inUsp1/ E18.5 embryos (Figure 7E). USP1 deficiency
did not alter osteoclast abundance or activity (Figures S6G–S6I),
excluding increased bone resorption in theUsp1/mice. Signif-
icantly, and in keeping with observations made in osteosarcoma
andmesenchymal stem cell cultures,Usp1/ femoral metaphy-
ses contained less ID1 and ID2 than their wild-type counterparts926 Cell 146, 918–930, September 16, 2011 ª2011 Elsevier Inc.(Figure 7D and Figure S6J). These data indicate that the USP1-ID
axis regulating differentiation in osteosarcoma is recapitulated
in normal skeletal development.
DISCUSSION
In this study we show that ID stabilization by USP1 sustains a
significant fraction of human osteosarcomas. USP1 was overex-
pressed frequently in primary osteosarcomas and osteosarcoma
cell lines (Figure 2), and by deubiquitinating the ID proteins
(Figures 1 and 3), inhibited bHLH-dependent expression of
CDKI p21 (Figure 4) resulting in unchecked cell proliferation
(Figure 5). USP1 overexpression not only was necessary for
the proliferation of several osteosarcoma cell lines, it also was
sufficient to prevent normal mesenchymal cell differentiation,
capturing the cells in a stem-like state (Figure 6). By contrast,
USP1 knockdown in osteosarcoma cell lines reduced expres-
sion of mesenchymal stem cell markers and initiated an osteo-
genic development program (Figure 5). USP1 deficiency in
mice impaired normal osteogenesis and resulted in pronounced
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Figure 7. USP1 Is Required for Normal Skeletogenesis
(A) Microcomputed tomography of 12-day-old Usp1+/+ (WT) and Usp1/ mice (top) and femurs (bottom).
(B and C) Mean bone mineralized density (BMD) (B) and mineralized bone volume (Minz. Vol.) (C) of mice in (A). Bars represent the mean ± SD of four femurs of
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(D) Western blot (WB) analysis of femoral metaphyses from E18.5 Usp1+/+ (WT) and Usp1/ mice.
(E) BALP in the sera of E18.5 Usp1+/+ (WT) and Usp1/ embryos. Bars represent the mean ± SD of four embryos of each genotype.
See also Figure S6.osteopenia (Figure 7). Therefore, we posit that overexpressed
USP1 interferes with mesenchymal stem cell differentiation
and thereby fosters the development of malignant mesenchymal
cell populations.
USP1 Is an ID DUB Overexpressed in Osteosarcoma
Our screen for DUBs capable of stabilizing ID2 (Figure S1)
identified both USP1 and USP33, although USP33 was unable
to deubiquitinate ID2 (data not shown). USP33 binding ID2
may have precluded ID2 recognition by the proteasome and
prevented its degradation. Other DUBs that enhanced ID2
expression in our screen did not appear to interact with ID2
and must influence ID2 abundance indirectly. These DUBs may
upregulate ID gene expression, interfere with the ubiquitin-
conjugation machinery, or otherwise impair proteasome func-
tion. For example USP9X may upregulate ID2 gene expression
by deubiquitinating and stabilizing the transcription factor
SMAD4 (Dupont et al., 2009).
The mechanism responsible for USP1 overexpression in a
subset of osteosarcomas (Figure 2) is unclear. USP1 mRNA
and protein levels correlated strongly implying transcriptional
upregulation. Notably, recent CGH analyses found that the
USP1 locus 1p31.3 was amplified in 26%–57%of osteosarcoma
tumors (Ozaki et al., 2003; Stock et al., 2000).
USP1 Promotes Proliferation via ID-Mediated
Repression of CDKI p21
We show that ID protein stabilization by USP1 disrupts bHLH-
dependent p21 expression in osteosarcoma (Figure 4 andFigure S3). Thus, USP1 overexpression perturbs normal osteo-
blast differentiation, which is characterized by p53-independent
upregulation of multiple CDKIs (Funato et al., 2001; Kenner et al.,
2004; Matsumoto et al., 1998; Yan et al., 1997; Zhang et al.,
1997). CDKI function often is compromised in osteosarcomas;
CDKN2A/p16INK4a and CDKN2B/p15INK4b gene deletions are
common (Miller et al., 1996; Nielsen et al., 1998), as is gene
inactivation due to promoter methylation (Oh et al., 2006). In
contrast, CDK4, a target of CDKIs, is frequently overexpressed
in osteosarcoma due to gene amplification (Ozaki et al., 2003).
ID-mediated transcriptional repression of p21 represents an
additional oncogenic mechanism in osteosarcoma.
ID protein overexpression has been observed in various
human cancers but has been attributed largely to increased ID
transcription (Perk et al., 2005). For example ID2 is transcription-
ally upregulated by the EWS-Ets translocation in Ewing’s
sarcoma (Nishimori et al., 2002), which is an osteoid tumor
bearing strong resemblance to osteosarcoma. Patients with a
disrupted copy of the RB1 gene are strongly sensitized to devel-
opment of osteosarcoma (Friend et al., 1986), RB being able to
sequester and inactivate ID2 (Iavarone et al., 1994; Lasorella
et al., 2000). Our study reveals an additional mechanism by
which ID proteins and, in turn, CDKIs can be dysregulated in
osteosarcoma.
ID Proteins Modulate Osteogenic Development
of Mesenchymal Precursors
Our data also implicate ID proteins in normal osteogenic devel-
opment. ID2 or USP1 overexpression inmesenchymal stem cellsCell 146, 918–930, September 16, 2011 ª2011 Elsevier Inc. 927
inhibited osteogenic differentiation and promoted retention of
mesenchymal stem cell features (Figure 6). These findings
support a recent study describing a role for ID proteins inmesen-
chymal differentiation (Peng et al., 2004). Intriguingly, Id1/Id3
compound heterozygous mutant mice display calvarial defects
and reduced osteoblast outgrowth (Maeda et al., 2004), sugges-
tive of a mesenchymal proliferation defect. It is unknown if
additional Id2 deficiency would exacerbate this phenotype due
to early lethality. Restricting Id gene deletion to the mesen-
chymal lineage may prove informative.
The osteopenia that occurs in Usp1/mice is consistent with
the phenotype predicted by USP1 knockdown in osteosarcoma
and USP1 overexpression in primary hMSCs (Figure 7 and Fig-
ure S6). In each setting our data suggest the USP1-ID axis
inhibits lineage commitment. An independent USP1-deficient
mouse strain also demonstrated runting and perinatal lethality
(Kim et al., 2009). Mice lacking multiple Id genes die early in
embryogenesis (Lyden et al., 1999), which could indicate that
an additional DUB regulates ID protein stability in early develop-
ment, or that other DUBs can compensate for the absence of
USP1.
Recent studies suggest that the bHLH proteins inhibited by
IDs 1–3 during osteogenesis may belong to the Hey/Hes family.
Hey1 overexpression promoted osteoblastic differentiation,
whereas Hey1 knockdown inhibited it (Sharff et al., 2009). Simi-
larly, Hes1 overexpression promoted osteocommitment (Suh
et al., 2008). It is possible that multiple bHLH transcription
factors act in parallel to promote osteoblast development.
USP1 and ID proteins would be positioned to broadly restrain
bHLH-driven commitment signals engaged during differentiation
of mesenchymal stem cells. We propose that USP1 belongs to
an emerging set of caulo-oncogenes that promotes tumorigen-
esis through subversion of normal stem (Latin ‘‘caulo’’) cell
biology.
A consequence of our findings, one that has significant
therapeutic ramifications, is that inhibition of USP1 protease
activity should institute a differentiation program in malignant
osteosarcoma leading to a precipitous decline in proliferative
capacity and potential reversal of the transformed phenotype.
Targeting USP1 would be expected to impact all USP1
substrates including FANCD2, but this may be beneficial
because defective DNA repair in tumor cells lacking a normal
p53 checkpoint is predicted to sensitize them to crosslinking
chemotherapeutic agents or PARP inhibitors (D’Andrea, 2010).
Differentiation treatments for cancer, as evidenced by the spec-
tacular success of arsenic as a differentiation therapy for acute
promyelocytic leukemia, provide an exciting option for the effec-
tive treatment of previously lethal cancers. Targeting USP1 may
provide such an opportunity for osteogenic sarcoma.
EXPERIMENTAL PROCEDURES
Cell Lines
Human 143B, 293T, HOS, MG-63, SAOS-2, SJSA, and U2-OS cells, murine
NIH 3T3 cells (ATCC), and primary human osteoblasts (PromoCell) were grown
in DMEM with 10% FBS (Sigma-Aldrich), 10 U/ml penicillin, and 10 mg/ml
streptomycin (GIBCO). Primary hMSCs derived from normal bone marrow
were cultured in hMSC medium (Lonza) or osteogenic differentiation medium
(Lonza) with 100 ng/ml BMP-9 (R&D Systems). Primary human osteosarcomas928 Cell 146, 918–930, September 16, 2011 ª2011 Elsevier Inc.were from CytoMix, LLC, and the CHTN. DT-40 cells from K. Patel (MRC-LMB)
were cultured in RPMI with 7% FBS and 3% chicken serum (GIBCO). Where
indicated, cells were treated with 10 mM MG-132 (Calbiochem) or 25 mg/ml
cycloheximide (Sigma-Aldrich). Complete experimental procedures are
available in the Extended Experimental Procedures.
Vectors
USP1 variants, ID1, ID2, and ID3 were in pRK2001 with or without a C-terminal
Flag epitope. A WDR48 expression vector was from OriGene. pMACS was
fromMiltenyi Biotec. ID2 and USP1 variants also were subcloned into pQCXIP
(Clontech) or pHUSH.Lenti.Puro (Genentech). Knockdown experiments used
pRS-based shRNA vectors (OriGene) or the pTRIPZ shRNA system (Open
Biosystems).
Transfections
Osteosarcoma cells were transfected with the plasmids indicated in combina-
tion with the marker plasmid pMACS using FuGENE 6 (Sigma-Aldrich).
Transfected cells were sorted with MACS-select H-2Kk microbeads (Miltenyi
Biotec). Proteins were extracted in lysis buffer (1% NP-40, 120 mM NaCl,
50 mM Tris-HCl [pH 7.4], and 1 mM EDTA) containing protease inhibitor
cocktail 1 and phosphatase inhibitor cocktails 1 and 2 (Calbiochem). For
dual shRNA/siRNA experiments, cells transfected with plasmids in FuGENE
6 then underwent nucleofection. DT-40 cells were transfected by
nucleofection.
Antibodies
Rat 5E10 anti-USP1 and 9F10 anti-WDR48 antibodies (Genentech) were
raised against the C-terminal 100 amino acids of the human proteins. Other
antibodies recognized ID1, ID2, ID3, E47, and p53 (Santa Cruz Biotechnology),
GAPDH (Assay Designs), Flag, HA, tubulin, and actin (Sigma-Aldrich), and p21
(Cell Signaling Technologies). Immunoprecipitations included 10 mM MG-132
and used protein A/G agarose beads (Pierce). Abcam AB52093 anti-ID2
antibody was used for immunohistochemistry in Figures 2E and 2F.
Gene Expression
RNA was extracted with RNeasy kits (QIAGEN) and amplified with the Quanti-
Tect SYBR Green RT-PCR system (QIAGEN). Primary tumor RNA data were
obtained from GeneLogic microarray analyses (Ocimum Biosolutions) with
HGU133P Affymetrix chips.
Flow Cytometry
Cells staining with FITC-conjugated anti-H-2Kk antibodies (Miltenyi Biotec)
were stained with propidium iodide (Sigma-Aldrich) in the presence of RNase
A (Sigma-Aldrich), and their DNA content was measured in a FACSCalibur
flow cytometer (BD Biosciences). Other antibodies used recognized CD90
(Chemicon), CD105 (R&D Systems), CD106 (SouthernBiotech), and CD144
(eBioscience).
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue sections were incubated in target
retrieval solution (Dako) at 99C for 20 min and cooled to 74C for 20 min.
Sections were blocked at room temperature in avidin/biotin blocking buffer
(Vector Labs) and then 3% BSA for 30 min. Staining with primary antibody
was at room temperature for 60 min. Sections were rinsed twice in Dako
wash buffer and then incubated in VECTASTAIN reagents (Vector Labs) for
30 min. Staining was revealed with peroxidase substrate buffer (Pierce), then
sections were counterstained with Mayer’s Hematoxylin. TRAP staining
(Sigma-Aldrich) was on 5 mm sections from formalin-fixed, paraffin-embedded
P12 mouse femurs. TRAP-positive osteoclasts were counted in ten fields.
Alizarin red staining was performed according to manufacturer instructions
(Ricca Chemical).
Immunofluorescence Staining
Stably transduced U2-OS cells treated with 3 mg/ml doxycycline (Clontech) for
14 days were fixed in 1% PFA in PBS and stained with antibodies recognizing
E-cadherin, N-cadherin (BD), or fibronectin (Calbiochem).
In Vivo Deubiquitination
Transfected 293T cells were cultured with 10 mM MG-132 for 30 min prior to
extraction in lysis buffer containing 10 mM MG-132 and 10 mM N-ethylmalei-
mide (Sigma-Aldrich). Soluble lysates were denatured with 1% SDS at 95C
for 5 min, then diluted 20-fold in lysis buffer prior to immunoprecipitation
with M2 anti-Flag agarose (Sigma-Aldrich).In Vitro Deubiquitination
293T cells were transfected with USP1-Flag, USP1-C90S-Flag, or ID2-Flag
and HA-ubiquitin. ID2-Flag was immunoprecipitated from SDS-denatured
cell lysate. USP1 was immunoprecipitated from regular cell lysate. Elutions
were with 500 mg/ml 3X Flag peptide (Sigma-Aldrich). Sampleswere combined
in DUB buffer (20 mM HEPES [pH 8.3], 20 mM NaCl, 100 mg/ml BSA, 500 mM
EDTA, 1 mM DTT) at room temperature.Osteosarcoma Differentiation
U2-OS, HOS, or SAOS cells transfected serially with pRS.shUSP1 (or shCTL)
were selected based on H-2Kk expression and cultured for 12 days. 143B cells
transduced with pTRIPZ inducible USP1 shRNA were selected in puromycin.
ALP activity was determined in cell lysates lacking phosphatase inhibitors after
normalizing for protein content. p-nitrophenyl phosphatase cleavage was
analyzed by colorimetric assay (Sigma-Aldrich).3T3 Transformation
Transduced 3T3 cells were plated in DMEM/0.5% low-melting agar on 1%
agar. Colonies of eight or more cells were scored visually after 21 days. For
ID knockdown, USP1-expressing 3T3 cells were transduced with pTRIPZ
inducible shRNAs and cultured with 3 mg/ml doxycycline for 72 hr prior to
embedding in agar containing 3 mg/ml doxycycline.Mice
Eight-week-old female NCr nude mice (Taconic) or C.B-17 SCID.bg mice
(CRL) were injected subcutaneously in the right hind flank with 1 3 106 3T3
cells or 2.53 106 143B cells in 100 ml HBSS and provided 1mg/ml doxycycline
in 5% sucrose water. Usp1 gene-targeted C57BL/6 ES cells were from the
Knockout Mouse Project Repository (Davis, CA). Microcomputed tomography
was a mCT 40 (SCANCO Medical). Amniotic fluid from E18.5 embryos was
assayed for deoxypyridinoline (TSZ ELISA), BALP (EIAab & USCNLIFE), and
creatinine (R&D Systems). The Genentech Institutional Animal Care and Use
Committee approved all animal studies.ACCESSION NUMBERS
mRNA expression data of USP1 were extracted from the Gene Logic expres-
sion database of Affymetrix HumanGenomeU133 Plus 2.0 data. The probe set
202412_s_at was chosen to represent the expression of USP1.SUPPLEMENTAL INFORMATION
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